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Abstract: Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the
accumulation of lipids in >5% of hepatocytes and the exclusion of secondary causes of fat
accumulation. NAFLD encompasses a wide spectrum of liver damage, extending from simple
steatosis or non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)—the latter is
characterized by inflammation and hepatocyte ballooning degeneration, in addition to the steatosis,
with or without fibrosis. NAFLD is now the most common cause of chronic liver disease in
Western countries and affects around one quarter of the general population. It is a multisystem
disorder, which is associated with an increased risk of type 2 diabetes mellitus as well as liver- and
cardiovascular-related mortality. Although earlier studies had suggested that NAFL is benign
(i.e., non-progressive), cumulative evidence challenges this dogma, and recent data suggest that
nearly 25% of those with NAFL may develop fibrosis. Importantly, NAFLD patients are more
susceptible to the toxic effects of alcohol, drugs, and other insults to the liver. This is likely due to the
functional impairment of steatotic hepatocytes, which is virtually undetectable by current clinical
tests. This review provides an overview of the current evidence on the clinical significance of NAFL
and discusses the molecular basis for NAFL development and progression.
Keywords: non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; benign condition;
disease progression; cardiovascular risk
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease
worldwide [1], and represents a major cause of severe liver complications, including cirrhosis and
hepatocellular carcinoma (HCC) [2]. The clinicopathological definition of NAFLD is the accumulation
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of fat in >5% of hepatocytes in the absence of secondary causes of fat accumulation, such as alcohol
consumption >30 gr per day in men or >20 gr per day in women [3,4], or the use of drugs that can
cause steatosis (e.g., amiodarone, steroids, tamoxifen, and others) [5]. This is important because
alcoholic liver damage is indistinguishable from NAFLD by biopsy [6]. Unfortunately, both types
of injury, either through excess calorie consumption or excess alcohol intake, often coexist in daily
clinical practice.
The spectrum of NAFLD encompasses a range of conditions from simple steatosis or non-alcoholic
fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), NASH fibrosis, NASH cirrhosis and
NASH-associated HCC as end-stage disease [2,7]. NAFL or liver steatosis is defined by fat accumulation
in liver tissue with only mild portal or lobular inflammation. Cellular injury, in the form of ballooning
degeneration and lobular inflammation in addition to steatosis, have to be present for the diagnosis of
NASH. Currently, the only reliable method to discern NAFL from NASH is histological evaluation after
liver biopsy. A recent meta-analysis estimated that the overall global prevalence of NAFLD diagnosed
by (ultrasound) imaging is around 25%, and the prevalence of NASH in the general population ranges
between 1.5% and 6.45% [1]. By now, NAFLD has reached epidemic proportions across the globe,
although there is a significant geographic variability [8]. Moreover, the prevalence of NAFLD is
continuously increasing worldwide, with 1.2 million new cases projected in the USA annually until
2030 [9].
NAFLD is strongly associated with obesity, type 2 diabetes mellitus (T2DM), and metabolic
syndrome (MS), a condition which is characterized by systemic inflammation and insulin resistance (IR),
although it is not definitely clear whether NAFLD is simply the liver correlate of the MS or if NAFLD
promotes development of MS and its component conditions (hypertension, T2DM, and cardiovascular
disease) [10,11]. Critical to any clinical risk assessment for an individual with NAFLD is that the main
cause of increased mortality is due to cardiovascular events [12].
The severity of liver fibrosis is the only histological finding that strongly predicts liver disease
progression and liver-related mortality of NAFLD [13,14]. However, it remains unclear if NAFL and
NASH are a continuum of disease stages and temporal transition, or if they are separate entities
diverging in the early course of the disease, depending on genetic, epigenetic, and various environmental
factors [15,16]. These diagnostic and prognostic uncertainties are confounded by sampling variability
from liver biopsy and the inhomogeneous distribution of steatosis and inflammation in the liver
tissue [17,18]. Moreover, there are few prospective longitudinal studies on NAFLD patients, with repeat
liver biopsies to monitor disease development and careful follow-up. This lack of data limits our ability
to fully discern the natural history of individual stages of NAFLD.
2. Can Patients with NAFL Progress to a More Advanced Disease Stage?
Without doubt, NASH and NASH fibrosis are associated with an increased risk of progression
to end-stage hepatic disease and development or worsening of a variety of extra-hepatic metabolic
complications [19]. In contrast major uncertainties remain if simple steatosis is truly a benign liver
condition. As mentioned above, more data on prospective disease monitoring by (multiple) repeat
biopsies are urgently required for a better understanding of the natural course of NAFLD. Reasons for
currently open questions and discrepancies between published reports include the mis-diagnosis of
liver disease, where patients with cryptogenic cirrhosis actually had NASH-related cirrhosis [20,21],
variable study duration and follow-up [22,23], as well as sampling variability from liver biopsy [17].
In the following section, we try to compile data on the one hand suggesting that NAFL or simple
steatosis is a benign condition (Table 1), and on the other hand, data suggesting that NAFL confers a
substantial risk of disease progression and the development of comorbidities (Table 2).
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Table 1. Evidence in favor of the good prognosis of NAFL patients.
Paired Liver
Biopsy # of Patients Endpoints Type of Study Observations Reference #
yes 40 natural history retrospective no progression to cirrhosis or liver-relatedcomplications; low number of patients [24]
no 132 cirrhosis outcome, overall mortality,liver-related mortality retrospective
poor outcome only in patients with
ballooning, Mallory hyaline or fibrosis [12]
no 209 liver-related mortality retrospective only fibrosis as independent factor ofliver-related mortality [25]
no 646 liver-related mortality, overall survival retrospective only fibrosis associated with liver-relatedmortality and overall survival [26]
yes 221 natural history of fibrosis progression;predictors of progression to F3 fibrosis
retrospective
systematic review
age and inflammation are predictors of
progression to advanced fibrosis [27]
Yes (n = 60) 129 survival and cause of death retrospective
survival is lower in NASH but not in simple
steatosis; low number of patients;
heterogeneity of patient population;
[28]
no 170 NAFLD246 ALD risk of cirrhosis development; risk of death retrospective
patients with simple steatosis have similar
survival to Danish population [29]
no 547 potential risk factors (index biopsy) forsurvival and cirrhosis development retrospective long-term follow-up study of ref. #31 [30]
No 619 long-term prognostic relevance ofhistologic features retrospective
only fibrosis showed decreased overall
survival, low number of patients with NASH
and without fibrosis
[13]
Abbreviations: NAFLD, non-alcoholic fatty liver disease; ALD, alcoholic liver disease.
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Table 2. Evidence in favor of the poor prognosis of NAFL patients (5 out of 6 with paired liver biopsies).
Paired Liver
Biopsy # of Patients Endpoints Type of Study Observations Reference #
yes 52 disease progression prospective longitudinalstudy
20–30% of patients with simple steatosis had
fibrosis progression; patients received
lifestyle advice and metabolic monitoring
[31]
yes 108 factors predicting progression onliver biopsy
progression to NASH in 44% of patients with
baseline NAFL [32]
yes 70 progression of simple steatosis and mildinflammation to NASH and fibrosis retrospective
ballooning in 16 of the 25 patients with
simple steatosis, and bridging fibrosis in 6 [16]
no 1515 (liverbiopsy cohort)
hepatic fat accumulation has a causal role in




long-term hepatic fat accumulation plays a







clinical risk factors associated
with progression
systematic review and
meta-analysis Liver fibrosis progresses in NAFL and NASH [34]
yes 103 histological course of patients withsequential liver biopsies retrospective
2 out of 3 patients with steatosis develop
NASH; 4 out of 4 patients with steatosis and
mild inflammation develop NASH; low
number of patients
[35]
no 10,568 mortality in NAFLD retrospective matchedcohort study
increased risk of mortality for all
histological stages
1.71-times increased risk in NAFL
[36]
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis.
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2.1. Evidence in Favor of the Good Prognosis of NAFL Patients
Several studies have argued against the possibility that simple steatosis can progress to fibrosis
progression and is associated with poor clinical outcome [24]. In 12 patients with bland steatosis
(no inflammation at all), a repeat liver biopsy was performed after 7.6–16 years, which did not show
progression to cirrhosis and patients had no serious liver complications [37]. Another study from
Younossi et al. demonstrated that only the presence of fibrosis of any degree remained an independent
predictor of liver-related mortality in the multivariate analysis [25]. In a large study (n = 646 patients)
with a mean follow up of 20 years (0–40 years range), Hagstrom et al. showed that fibrosis stage is
directly associated with liver-related mortality and overall survival [26]. A systematic review including
10 longitudinal NASH biopsy studies comprising a total of 221 patients described that age and portal
inflammation on initial biopsy are independent predictors of progression to advanced fibrosis in
patients with NASH [27]. In a study comprising 728 adults and 205 children from the Nonalcoholic
Steatohepatitis Clinical Research Network increased portal chronic inflammation was associated with
progressive NAFLD in both adults and children [38]. One hallmark study of Ekstedt et al. analyzed
survival and causes of death in a cohort study of 129 patients diagnosed with biopsy-proven NAFLD in
comparison with a matched reference population. From the initial cohort, 88 patients were reevaluated,
and in 68, a repeat liver biopsy could be performed. The authors observed that the overall survival of
NAFLD patients was significantly lower than that of the reference population. When separating this
population in histologically confirmed NASH or steatosis with no or mild inflammation survival was
significantly reduced only in NASH patients [28]. It is important to recognize that this study was limited
by heterogeneity of the patient population and the low number of patients included. A follow-up study
on this important work by the same group focused on different causes of mortality [14]. The core finding
of this work was that a fibrosis stage of 3 or 4, independent of NAS/presence of NASH, was associated
with an increased risk for overall, cardiovascular and liver related mortality. NASH without significant
fibrosis (stages 0–2) was associated only with an increased mortality risk from HCC. Patients with
a NAS < 5 (NAFL or borderline NASH) with fibrosis stages 0–2 exhibit no significantly increased
mortality risk compared to the control population. Of note, the proportion of patients with stage
3–4 fibrosis was similar in patients with NAS < 5 (5%) and in patients with NAS ≥ 5 (5%). A limitation
of this study was that the reference cohort was selected from population data, without any information
on BMI, factors of the metabolic syndrome or hepatic steatosis.
Two studies by Dam-Larsen et al. on individuals with histologically confirmed steatosis/fatty
liver without inflammation or fibrosis compared those with NAFLD (170) to patients with alcoholic
liver disease (AFLD; 246). In this comparison it was observed that the prognosis in patients with
NAFLD was good as only 1.2% progressed to cirrhosis compared to 22% of AFLD [29,30]; 48 (28%) of
NAFLD patients and 188 (76%) of AFLD patients died during the follow up period (median 12.8 years).
Cardiovascular events (37%) and extrahepatic cancer (17%) were the leading causes in NAFLD,
and cardiovascular events (20%) followed by cirrhosis (17%) were the main causes of death in AFLD.
Central limitations of this study was that histological assessment was limited to steatosis and fibrosis
and that BMI was only available for 35% of AFLD patients.
Angulo et al. performed a retrospective longitudinal analysis of 619 patients with NAFLD at
centers in the United States, Europe, and Thailand over a period between 1975 and 2005 [13]. The central
finding was that a total of 193 patients (33.2%) died or underwent liver transplantation. In multivariable
analysis, only patients with fibrosis had shorter overall survival in comparison with patients without
fibrosis. Limitations of the study included the low number of patients with NASH but without fibrosis,
and that the mortality in the control group without NASH and fibrosis was significantly higher than
previously reported.
The studies summarized herein (Table 1) show unmistakably that the main liver-related risk in
NAFLD arises from advanced fibrosis and cirrhosis and that at least liver-related mortality is driven by
NASH. However, this does not in itself imply that NAFL or steatosis without significant inflammation
is without risk.
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2.2. Evidence of Progression from Steatosis to Fibrosing-Steatohepatitis and Mortality in NAFL
Although the above described early studies demonstrated a different outcome in NAFLD patients
based on the presence or absence of NASH, there is growing evidence challenging the dogma that NAFL
is a non-progressive disease. Contrary to the claim that NAFL is a benign condition, several studies
provide data objecting this statement (Table 2). In a prospective study of 52 patients with paired
liver biopsies, it was observed that 28% of patients with a NAS below 5 had fibrosis progression.
Moreover, 17 of 29 (58%) NAFL patients (NAS < 3) progressed to borderline NASH or NASH [31].
The conclusions of this study should be taken with caution because all patients in this study received
lifestyle advice and metabolic monitoring, which might have altered the natural course of the disease
and because the sample size in each subgroup is small.
In another study data of 108 patients with NAFLD were analyzed, who had serial liver biopsies
after a median of 6.6 years (1.3–22.6 years) [32]. The authors observed progression to NASH in 44% of
patients with baseline NAFL. Of 27 NAFL patients 10 (37%) progressed to fibrosis, all 10 exhibited
NASH in the follow-up biopsy. Of those NAFL patients with fibrosis progression 6 reached stage
3 fibrosis at follow-up biopsy. T2DM was present in 80% of NAFL patients with fibrosis progression
but only in 25% of NAFL patients without progression. These findings are in line with a study on
seventy patients with untreated NAFLD (25 with simple steatosis and 45 with NASH) with follow
up biopsy after a mean duration of 3.7 years between 1998 and 2009 [16]. A substantial proportion
(64%) of the 25 patients with simple steatosis on initial biopsy progressed to NASH. Severe ballooning
was observed in eight and bridging fibrosis in six NAFL patients progressing to NASH. Of note
ballooning progression and fibrosis was paralleled with a reduction in ALT. This finding supports the
notion that classic liver enzymes (ALT and AST) are not useful for diagnosis, follow up, or disease
monitoring in NAFLD [39]. Previous studies found high proportions of patients with liver enzymes
in normal range with NASH or even advanced fibrosis [40–42]. Our own unpublished data of over
250 obese individuals with biopsy proven NAFLD resulted in significant differences of AST and
ALT between patients with steatosis and patients with NASH. However, to allow discrimination of
steatosis and NASH cut off concentrations around 19 U/l would have to be chosen with insufficient
sensitivities and specificities (unpublished data). In a sample of outpatients in a gastroenterology
unit, who were diagnosed with liver steatosis by ultrasound only, we found that cardiovascular and
metabolic risk factors were significantly more common than in patients without liver steatosis [43].
This effect was independent of the underlying cause of the outpatient visit. This finding suggests that
liver steatosis detectable by ultrasound may already be sufficient to indicate elevated cardiovascular
risk, independent of definite NAFL or NASH diagnosis.
Mendelian randomization is an epidemiological method that avoids confounding factors (such as
diet or physical activity) and is aimed to avoid reverse causation in observational studies [44].
Applying mendelian randomization Dongiovanni et al. analyzed data of more than 9000 individuals
from the liver biopsy cohort (LBC), the Swedish Obese Subjects Study (SOS), and the population-based
Dallas Heart Study (DHS) [33]. The risk alleles of PNPLA3, TM6SF2, GCKR and MBOAT7 and their
effect on hepatic steatosis were evaluated in a polygenic risk score. The extent of hepatic steatosis was
associated with liver damage, insulin resistance, dyslipidemia and hypertension. Strikingly the impact
of genetic variants on liver damage was proportional to their effect on lipid accumulation in the liver.
Within the LBC, hepatic fat and fibrosis were associated independently of inflammation, suggesting a
causal effect of steatosis on fibrogenesis. Overall, the data of this meticulous analysis of a very large
number of patients suggests that at least the genetically determined proportion of hepatic steatosis
is likely to be a causal risk factor for the development of liver fibrosis and extent of liver damage
in NAFLD.
A systematic review and meta-analysis was performed by Singh et al. on 11 studies,
including 411 patients with biopsy-proven NAFL and NASH who underwent paired liver biopsies at
least one year apart. From six studies, the fibrosis progression rate (FBR) in 133 NAFL patients could
be calculated, with 52 (39.1%) patients developing progressive fibrosis. From seven studies, FBR for
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116 patients with NASH was derived, with 40 (34.5%) developing progressive fibrosis. The annual FBR
was 0.07 stages in NAFL and 0.14 stages in NASH, resulting in a progression of one stage in 14.3 years
for NAFL and in 7.1 years for NASH. It should be noted that while the rate of progression was slower in
NAFL, the proportion of patients who actually exhibited fibrosis progression did not differ significantly
between NAFL and NASH [34]. Limitations of this meta-analysis include the heterogeneity of the
studies analyzed, and that seven of them enrolled less than 25 patients.
Adams et al. analyzed the natural history of 103 patients, who underwent serial liver biopsies
with a mean interval between biopsies of 3.2 ± 3.0 years [35]. When excluding cirrhotic patients,
who cannot further progress, the annual FBR in these patients was 0.09 ± 0.67, which corresponds to
the overall FBR of NAFLD found by Singh et al. [34]. NASH was present in 96 (93%) of the 103 patients.
Of the three patients with bland steatosis on initial biopsy, two developed NASH. All four patients
with steatosis and nonspecific inflammation on initial biopsy developed NASH. The proportion of
patients who progressed in fibrosis stage (overall 37%) did not differ significantly between NAFL
(34.4%) and NASH (53.8%). The main determinant of fibrosis progression over time was the fibrosis
stage on initial biopsy, with lower stages (0–2) at higher risk. Progressive inflammation, steatosis,
and ballooning were not associated with fibrosis progression. Of note, progression of fibrosis stage
was associated with a reduction in ALT and AST as well as severity of steatosis. The findings of this
study are limited by the very low number of NAFL patients (9).
In the above described study by Eksted et al. that demonstrated increased mortality only in NASH
patients [28], a histological course was also analyzed in available repeat biopsies. Progressive fibrosis
was observed in 29 of 70 (41%) of NAFLD patients. In patients with steatosis without fibrosis, 17 of 36
(47%) developed fibrosis. It should be noted that this study was performed in patients with elevated
serum AST or ALT, which preselects patients with more severe disease course. Moreover, patients with
NASH in this cohort were significantly older (54.5 ± 12.4 years) than those with steatosis, with or
without unspecific inflammation (46.7 ± 12.3 years). The most recent analysis from a matched cohort
study of all Swedish patients with biopsy confirmed NAFLD (10568 patients) found an increased
risk of mortality for all histological stages [36]. Compared to age, sex, and location matched controls
of the general population, the mortality risk was 1.71-times higher in simple steatosis, 2.14-times
higher in non-fibrotic NASH, 2.44-times higher in non-cirrhotic fibrosis, and 3.79-times higher
in cirrhosis. The NAFLD-associated excess mortality derived from extrahepatic cancer, cirrhosis,
cardiovascular disease and hepatocellular carcinoma.
The results summarized above collectively support the concept that NAFL can progress to NASH
with fibrosis, mainly in patients who have poor metabolic control. Some studies suggest that fibrosis
can even develop or progress without a transition from NAFL to NASH. Overall roughly 30–40% of
NAFL patients seem to exhibit progression of fibrosis in studies with sequential biopsies. In some
cases, this progression occurred within a relatively short time frame. These observations should be
taken with some caution. On the one hand, sampling variability between two liver biopsies due to
the inhomogeneous distribution of inflammation and ballooning might lead to incorrect classification
of a region with lower disease activity, and subsequently ‘disease progression’ upon second biopsy
in a region of representative disease activity. On the other hand, we need to consider the possibility
of selection bias in studies which examined only those with follow-up biopsies, as these are usually
individuals most at risk and/or likely to progress [45]. However, a proportion of 30–40% with disease
progression would imply a substantial variability or observer error in histological assessment.
Regarding mortality, there is no doubt that histologically proven NASH and in particular advanced
fibrosis and cirrhosis are associated with a higher risk of overall and especially liver-related mortality.
Though, NAFLD as a whole exhibits increased mortality rates compared to the general population.
A recent analysis suggested that up to 29% of healthy controls may actually have NAFLD [46],
masking a part of the impact of NAFLD on health and clinical outcomes. Some studies referred to
above used population based controls without correction for BMI or metabolic morbidities to compare
mortality to NAFLD or NAFL patients. This would probably underestimate the true effect of NAFLD
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on mortality, especially as non-cirrhotic stages and even compensated cirrhosis in NAFLD are still
widely underdiagnosed in daily practice [47].
EASL Clinical Practice Guidelines indicate that NAFL patients without worsening metabolic risk
factors should be monitored at 2–3-year intervals considering the low risk of progression for this group
of patients [48], although this may be a too long an interval for patients with an underestimated risk of
progression. Thus, it is imperative to identify reliable risk factors for progression and subsequently
improve the surveillance of patients with NAFL at risk of progression. Currently the disease progression
of any NAFLD patient cannot be excluded with certainty, and thus it is mandatory to improve the
efficacy of surveillance to prevent as many liver-related and other metabolic complications as possible.
3. Pathophysiological and Molecular Mechanisms of Non-Alcoholic Fatty Liver Disease
NAFLD is the consequence of excess calorie intake (from overnutrition and inactivity)
and subsequent adipose tissue hypertrophy, with different combinations of genetic, epigenetic,
environmental and metabolic factors interacting in development and influencing the severity of the
disease. This complex genesis makes understanding of this disease a true challenge; though, it is
now widely accepted that NAFLD is a multifactorial disease (Figure 1). The previous “two sequential
hits pathogenesis” theory was based on insulin resistance (IR) and its stimulation of triglyceride (TG)
deposits within the liver as initial hit, which is followed by a “second hit” induced by oxidative
stress or ATP depletion, which further induces apoptosis, inflammation and fibrosis [49]. This theory
has been replaced by the “multiple parallel hits theory”, in which several factors act in parallel and
different combinations, sometimes synergistically, generating NAFLD [50]. This situation limits the
development of pharmacological interventions, which could help the majority of patients, in contrast
to HBV or HCV, where a single factor is causative for the disease. Patients with NAFLD seem to have
individually different disease courses with varying contribution of IR and genetics [33] and some of
them directly develop NASH while others (seem to) progress sequentially from NAFL to NASH [51].
Approximately 25–30% of patients with simple steatosis will develop NASH, and thus it is important
to understand the molecular mechanisms involved and how to treat or prevent this complex disease.
In this chapter of the review, we will discuss known key pathogenic factors involved in the genesis of
NAFLD on a molecular level.
3.1. Genetic Factors Involved in NAFLD
By now it is clear that genetic factors contribute to the pathogenesis of NAFLD. Genome-wide
association and gene expression profiling have identified genes with a number of polymorphisms
associated with NAFLD development such as Patatin-like phospholipase domain containing
3 (PNPLA3), Transmembrane protein 6 superfamily member 2 (TM6SF2), GCKR, CETO, MBOAT7,
MTTP, SOD2, GST, APOC3, IL-6, TNF-a, PPAR-a, just to mention a few [52]. In general, these genes
or their products are involved in one or more of the following processes: lipid and glucose
metabolism, insulin signaling pathways, oxidative stress (OS), detoxification, inflammatory pathways,
and fibrogenesis. The two most studied and best characterized are PNPLA3 and TM6SF2 [52].
PNPLA3 is highly expressed in the liver and adipose tissue [53].
Although the function of PNPLA3 is not completely defined, it is considered to have lipogenic
transacetylase activity. Presence of the PNPLA3 SNP rs738409 (I148M) promotes lipid storage in the
liver, mainly because of a deficient glycerolipid hydrolase activity [53]. This effect seems to be more
pronounced in normal-weight subjects than in overweight subjects [54,55]. The PNPLA3 variant allele
rs738409 C>G has been associated with the risk and severity of NAFLD (inflammation, and progression
to fibrosis) and even with HCC development [56]. PNPLA3 is a strong modifier of the natural history
of NAFLD and can be considered as a potential target for therapy.
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NAFLD develops due to excess calorie intake, which leads to adipose tissue hypertrophy.
Adipose tissue confronted with nutrient ov rload will increase lipolysis and change secretion of
adipokine . This altered systemic s tuation of nutrients, lipid and adipokines, ultimately resulting
in NAFLD, is modulated by , pigenetic, environmental and metabolic factors (oute ring).
Various molecular and cellular mechanisms (cogs) in eract in development of NAFLD and NASH.
Abbrevations: ATP: adenosine triphosphate; β-oxi ti : t xidation of lipid components within
mitochondria; DNL: de novo lip sis; str ss: endoplasmatic retic lum stress; FFA: free fatty
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The TM6SF2 SNP rs58542926 C>T confers a significant genetic susceptibility for NAFLD and
disease severity [57,58]; surprisingly, this mutation might confer cardiovascular protection [59].
The TM6SF2 variant has been associated with higher serum ALT and AST levels, and reduced
plasma levels of TG and LDL-cholesterol [60]. In a mouse model, TM6SF2 silencing using an
adeno-associated virus (AAV) vector increases hepatic TG levels and decreases plasma levels of TG,
LDL- and H L-cholesterols, demonstrating a key role f the TM6SF2 gene i hepatic TG secretion
regulation [57].
Although ge etic te ting i NAFLD currently remains in the realm of research, it is likely that this
could soon be in routine clinical practice, either as a prognostic indicator, or to risk stratify individuals
for treatment. For example, individuals who are carriers of one or both alleles may be more at risk of
progressive liver disease and therefore, could be targeted for more intensive surveillance, and/or receive
therapy. However, it must be clear that the presence of the above described SNPs increases the risk to
develop NAFLD or for a more severe course, but do not inevitably result in NASH.
3.2. Insulin Resistance
IR is one of the first metabolic changes occurring in overweight and obese individuals,
associated with the systemic inflammatory state induced by obesity, often leading to more
severe metabolic consequences. Adipose tissue inflammation and an altered adipokine profile
Cells 2020, 9, 2458 10 of 19
promote peripheral IR. Hepatic IR with continued nutrient excess leads to lipotoxicity, ER stress,
mitochondrial dysfunction, impaired autophagy, altered gut microbiota, which all promote progression
from NAFL to NASH [50].
The detailed molecular mechanisms of IR that promote NAFLD development remain unclear.
What is known is that under a chronic over-nutrition state and adipose tissue inflammation, an altered
adipokine profile promotes a systemic inflammatory state, which further induces peripheral IR [61,62].
Adipose tissue IR promotes lipolysis, thus leading to an increase in circulating free fatty acids (FFA),
which are then taken up by the liver for lipogenesis. In addition, gluconeogenesis and de novo
lipogenesis (DNL) are stimulated [63]. In general, the transition from NAFL to NASH occurs in
the presence of IR, however, the triggering events and molecular mechanisms regulating disease
progression remain poorly understood.
3.3. Lipid Metabolism and Lipotoxicity
Excessive hepatic accumulation of fatty acids constitutes the initial step of steatosis. In NAFLD
patients, 59% of FFA are derived from deregulated lipolysis in adipose tissue, while the remaining 26%
come from hepatic DNL, and only 15% originate from the diet [64]. Patients with high liver fat content
exhibit at least threefold higher levels of DNL when compared with individuals with low liver fat
content despite similar levels of FFA flux from the adipose tissue; therefore, DNL is a major contributor
to the development of steatosis, apart from lipolysis [65]. Activation of the transcription factors sterol
regulatory binding protein-1c (SREBP-1c) and the carbohydrate response element-binding protein
(ChREBP) are crucial steps for DNL and FFA uptake [66]. Dietary cholesterol, dietary saturated fatty
acid or hyperinsulinemia activate SREBP1c; chREBP is activated by hyperglycemia [67]. SREBP1c and
ChREBP transactivate genes involved in FFA metabolism, including those required for FFA uptake
(e.g., FABP3, FABP4, CD36), DNL (e.g., FASN and ACC1) and triglycerides (TG) synthesis (e.g., GPAT).
Nevertheless, lipid accumulation is not necessarily harmful. The type of lipid and not the amount
of lipids seems to determine lipotoxicity in hepatocytes [68]. Both TG storage in lipid droplets or
TG export via VLDL secretion appear to have a protective role for the liver. In fact, transgenic mice
overexpressing diacylglycerol acyltransferase 2 (DGAT2), which catalyzes the final step of TG
synthesis, developed hepatic steatosis with reduced necro-inflammation [69]. Not lipid accumulation
per se, but lipid composition seems to be crucial for disease progression from NAFL to NASH.
While some lipid species are lipotoxic, others may protect cells from lipotoxicity. In contrast to
unsaturated FFA, saturated FFA are detrimental to cell viability [70]. Unsaturated FFA (e.g., oleic acid)
induce TG formation, which results in a mechanism of defense against the pro-apoptotic stimuli
of large loads of saturated FFA [71,72]. Several other lipid metabolites, such as diacylglycerol,
lysophosphatidyl choline, free cholesterol, cholesterol ester, ceramide, and bile acids, also accumulate
in hepatic cells, and they promote ER stress, which leads to the execution of pro-apoptotic pathways and
stimulates pro-inflammatory signals that activate Kupffer cells and HSCs, and induce mitochondrial
dysfunction and ROS [73–76]. Alterations in bile acid composition and excretion contribute additionally
to liver injury in NAFLD [74,76,77].
3.4. ER Stress
Endoplasmic reticulum (ER) stress is the result of the accumulation of unfolded/misfolded
proteins within the ER, which is enhanced by oxidative stress (OS) [78]. Under healthy physiological
conditions, reactive oxygen species (ROS) are produced in hepatocytes (mainly within the mitochondria),
i.e., by FFA oxidation. However, when ROS are generated in excess, are not eliminated, or converted
(e.g., to a less toxic compound) they can initiate cell death [79]. Excessive ROS production leads to lipid
peroxidation and protein misfolding due to oxidation of polyunsaturated fatty acids and sulfhydryl
group proteins, respectively, which are common events in NAFLD [80]. ER stress stimulates lipid
droplets accumulation in the liver in a SREBP-dependent process [81]. It has been demonstrated that
SREBPs, transcriptional master-regulators for fatty acid and cholesterol synthesis, are upregulated
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by OS and ER stress leading to lipid accumulation generated by DNL, TG, and cholesterol deposits
in the liver [82]. Conversely, increased hepatocyte lipid content can also initiate and perpetuate
chronic ER stress [83]. In addition, OS and ER stress interfere with lipoprotein secretion from the
liver [84]. In addition, the unfolded protein response (UPR) is linked to the activation of DNL
pathways, further increasing steatosis [85]. Chronic activation of UPR also induces hepatocyte death
and inflammation [86]. The interaction of increased lipid uptake, DNL, and reduced lipoprotein
secretion result in a fatty liver. The continued generation of ROS, i.e., by sustained FFA oxidation,
can promote progression of NAFL to NASH.
Thus, the presence of OS and, consequently, ER stress are key players in the pathogenesis
of NAFLD and progression to NASH. Importantly, ER stress can be pharmacologically targeted,
e.g., by the use of antioxidants (vitamin E) aiming at reducing excessive ROS production.
3.5. Mitochondrial Dysfunction
Increased mitochondrial activity is crucial to protect hepatocytes from the deleterious effect of
FFA deposition since FFAs are oxidized by mitochondrial β-oxidation [87,88]. NAFL induces PPAR-α,
which promotes FFA delivery to the mitochondria via CPT-1. However, during NAFLD development
enhanced mitochondrial FFA β-oxidation leads to OS due to exacerbated leakage of electrons from the
electron transport chain. This disrupts the balance between FFA removal and ROS generation [89].
Elevated ROS concentrations in the mitochondrial environment due to excess FFA may further
damage the organelle function establishing a vicious circle. Hepatic mitochondria are structurally
and molecularly altered in NAFLD [90], including electron transport chain alterations, and reduced
ATP synthesis, which further induces ER stress. Increased mitochondrial cholesterol deposits induce
changes in membrane permeability, and mitochondrial dysfunction; both processes have been linked
to the progression of NAFL to NASH [79]. When ROS are produced in excess, both mitochondrial
and nuclear DNA are damaged, impairing the transcription of mitochondrial proteins involved in
metabolism and organelle biogenesis [91,92], which further aggravates the situation. Taken together
impaired mitochondrial lipid peroxidation under a continuous supply of FFA leads to a vicious circle
of excess ROS generation, ER stress, lipid accumulation, and mitochondrial impairment or damage.
Currently, there are no known agents to inhibit this vicious circle apart from drastically reducing the
influx of additional FFA, i.e., radical lifestyle change.
4. NAFLD Patients Are More Susceptible to Liver Injury Generated by Drugs and Alcohol
As described above simple steatosis is still considered generally a benign disorder, unlike NASH.
Apart from the above described direct liver related and cardiovascular consequences of NAFL and
NASH, several studies have shown that NAFLD worsens most conditions that injure the liver,
suggesting increased sensitivity to viral hepatitides, alcohol, and drugs [93]. It is generally accepted
that NAFLD patients will be more likely to be injured than healthy individuals by the same drug and
dose [94,95]. In addition, drug-induced liver injury (DILI) remains a major concern for investigators in
NASH clinical trials, and there are no evidence-based recommendations for best practices related to
DILI in NAFLD patients [96]. In fact, the US Drug Induced Liver Injury Network (DILIN) reported
recently that DILI in patients with chronic liver disease (including hepatitis C and NAFLD) was
associated with more frequent adverse events, including mortality [97].
Different predisposing factors inherent to patients are known to enhance the risk of DILI including
NAFLD and obesity [98–100]. In a prospective study on 248 patients with either HCV or NAFLD,
NAFLD patients had a 3.95-fold risk of DILI compared to HCV [98]. NAFLD is associated with
obesity, diabetes, hyperlipidemia, and other chronic diseases that require long-term and multiple drug
administration. Therefore, increasing the risk of hepatic adverse effects or toxicity [101]. As such,
clinicians should be aware of the added risk of liver injury in patients with chronic liver diseases,
especially in NAFLD [102–104]. Apparently patients with NAFLD and/or obesity are more likely to
suffer from drug-induced acute liver injury. NAFLD patients are also at risk of progression from NAFL
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to NASH as a result of DILI [100], at least for some types of drugs (e.g., acetaminophen, halothane,
methotrexaye, pentoxufylline, rosiglitazone, tamoxifen) [105].
The increased susceptibility for drug-induced acute liver damage could be caused by various
mechanisms, separately or in combination, such as increased expression of CYP2E1, inflammation,
and reduced mitochondria respiratory chain activity; these might lead to increased ROS production,
decreased ATP synthesis and production of pro-inflammatory cytokines (e.g., TNF-α) [106]. In addition,
drug-induced liver damage (more frequently by isoflurane, acetaminophen, losartan, ticlopidine,
and omeprazole) could be aggravated by the generation of higher levels of toxic metabolites
produced by increased activity of CYP isoforms including CYP2E1 in obese individuals with
NAFLD [94,98,99,107,108]. It has been shown that, in human liver samples, steatosis was associated
with decreased hepatic cytochrome P450 3A (CYP3A) activity, which seems to be related to the severity
of hepatic steatosis [109]. However, the link between decreased CYP3A activity and DILI in NAFLD
patients is not robust.
Caregivers should consider that chronic administration of some drugs can worsen pre-existing
NAFLD. Chronic alcohol intake in particular is detrimental to the steatotic liver as it may worsen the
clinical course of NAFLD [110–113]. One study demonstrated a 5.3-fold risk of mortality for obese
males drinking 1–14 drinks per week and a 18.9-fold risk of mortality for obese males drinking 15
or more drinks per week compared to normal weight non-drinkers [111]. Indeed, both drugs and
alcohol can accelerate the transition from NAFL to NASH by increasing DNL, limiting the excretion of
VLDL, and reducing fatty acid oxidation. In parallel the expression of pro-inflammatory cytokines,
ROS production, and ER stress are further increased and mitochondrial respiratory chain activity is
reduced [94,105,113,114].
Taken together, it is likely that NAFLD predisposes an individual to more severe liver injury
by factors causing acute injury of hepatocytes as drugs, viral hepatitides, and alcohol. It should be
noted that many of the above-referenced studies do not histologically discern NAFL from NASH.
Therefore, it cannot be excluded that NAFL or liver steatosis alone could already enhance the risk of
liver injury and/or aggravate the severity of liver injury, albeit probably to a lower extent than NASH.
5. COVID-19 and NAFLD
Coronavirus disease 2019 (COVID-19) is caused by a pathogen named Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2) [115,116]. In general, liver injury in COVID-19 patients was
frequent but mild, and a clear association between any underlying hepatic disease with the course of
the SARS-CoV-2 infection was not established. Underlying pathophysiological mechanisms of liver
injury in COVID-19 remain largely unknown. However, in a series of 202 consecutive patients admitted
(from January through February) to two COVID-19-designated hospitals in China up to March 2020,
76 (37.2%) had NAFLD [117]. The authors observed that patients with NAFLD showed a higher risk
of disease progression to a more severe disease, and more persistent viral shedding in comparison
with non-NAFLD patients [117]. In line with this, the EASL and ESCMID recommend to patients with
NAFLD or NASH, which in addition may suffer from hypertension, diabetes and obesity, to adhere to
physical distancing because they are at risk of a severe course of COVID-19 [118,119]. Another important
issue in the scenario of COVID-19 in patients with chronic liver diseases, which includes NAFLD
or NASH, is related to the use of experimental drugs that have been tested (such as chloroquine,
hydroxychloroquine, lopinavir/ritonavir, remdesivir, camostat, tocilizumab, emapalumab, anakinra,
among many others) to mitigate the most severe complications. Although clinicians have to keep
in mind potential side effects of these drugs, it is also recommended to consider these patients for
early treatment as they are at risk of progression [119]. Altogether, efforts should be made to better
understand the role of NAFLD in COVID-19, and to be alert to the consequences of COVID-19 in
patients with NALFD.
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6. Concluding Remarks
In summary, cumulative data show that NAFLD (which includes NAFL and NASH) may progress
to severe chronic liver disease. NAFLD is also a risk factor for the development of other metabolic
diseases (diabetes, cardiovascular disease) and may aggravate any other underlying liver disease.
As such, clinical providers will need to recognize that NAFL/liver steatosis is not necessarily benign.
As there is currently no non-invasive marker that can accurately and reliably distinguish NAFL
from NASH, providers will have to use their clinical judgement in association with available tools
to identify individuals likely to progress. While it seems obvious that NASH confers a greater
risk of liver-related and overall morbidity and mortality than NAFL, NAFL is not without risk.
In particular, progressive fibrosis and the development of cardiovascular morbidity occur in a similar
proportion of NAFL and NASH patients. In conclusion, any patient with NAFLD must be considered
an at-risk patient for the progression of liver disease and for the development of components of
metabolic syndrome.
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